Anastrozole Tablet
Product Images NDC 63187-080

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 63187-080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Anastrozole 1mg (Anastrozole 1mg 30 Label)

Label for Anastrozole 1 mg tablets, prescription drug by Proficient Rx LP. The label states the package contains 30 tablets, each with 1 mg of Anastrozole USP. Tablets are described as white to off-white, round biconvex, film-coated with "AHI" debossing. Manufactured by Intas Pharmaceuticals Limited in India. Storage instructions and barcodes are also shown.*

FDA Label Image

Figure 1 (Anastrozole Fig1)

A Kaplan-Meier survival curve comparing disease-free survival over time in months for two randomized treatments: anastrozole and tamoxifen. The vertical axis represents the proportion alive and disease-free, ranging from 0 to 1, and the horizontal axis shows time in months up to 96. A table below lists the number of patients at risk for each treatment at specified time points.*

FDA Label Image

Figure 2 (Anastrozole Fig2)

A Kaplan-Meier survival curve graph comparing disease-free survival over 96 months between treatments with anastrozole and tamoxifen. The y-axis shows the proportion of patients alive and disease-free, and the x-axis shows time in months. The graph includes a table showing the number of patients at risk over time for each treatment group.*

FDA Label Image

Figure 3 (Anastrozole Fig3)

A Kaplan-Meier survival curve graph comparing the proportion of patients remaining recurrence free over time (in months) between two treatment groups: Anastrozole and Tamoxifen. The x-axis shows time to event in months up to 120 months, and the y-axis shows proportion recurrence free from 0.5 to 1.0. The graph includes the number of patients at risk for both groups at various time points below the x-axis.*

FDA Label Image

Figure 4 (Anastrozole Fig4)

A Kaplan-Meier survival curve comparing the proportion of patients event-free over time up to 120 months between two randomized treatment groups: Anastrozole and Tamoxifen. The y-axis shows the proportion event-free, and the x-axis shows time to event in months. The graph includes the number of patients at risk at various time points for each group below the x-axis.*

FDA Label Image

Figure 5 (Anastrozole Fig5)

A Kaplan-Meier survival curve chart comparing time to progression (months) between two randomized treatments, Anastrozole and Tamoxifen. The vertical axis shows the proportion not progressing, and the horizontal axis represents months from 0 to 32. The curves illustrate the progression-free proportions over time for both treatments.*

FDA Label Image

Figure 6 (Anastrozole Fig6)

A Kaplan-Meier survival curve comparing progression-free proportion over time (in months) between randomized treatments with Anastrozole and Tamoxifen. The x-axis represents time to progression in months, and the y-axis shows the proportion not progressed, with data points from 0 to 42 months.*

FDA Label Image

Chemical Structure For Anastrozole (Anastrozole Str)

Chemical structure diagram of Anastrozole, showing its molecular arrangement with a triazole ring attached to a substituted benzene ring with nitrile and methyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.